Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Eli Lilly and other pharma firms have begun submitting their anti-amyloid drug hopefuls for approval. But questions linger over the controversial precedent set by Biogen’s aducanumab.
Despite 30 years of climate diplomacy, urgent and aggressive action is needed to halt global warming. Nature explains what success looks like, and what’s on the line.
A special report outlines the challenges — from unleashing the power of mRNA vaccines, to the battle for temporary relief on intellectual-property rights.
Results confirming the vaccine’s strong protection against COVID-19 were welcomed following last week’s pause in roll-outs — but fresh questions have now emerged about the data.